MCID: HMG002
MIFTS: 50

Hemoglobinuria

Categories: Blood diseases, Immune diseases, Nephrological diseases

Aliases & Classifications for Hemoglobinuria

Summaries for Hemoglobinuria

MalaCards based summary : Hemoglobinuria is related to paroxysmal nocturnal hemoglobinuria 1 and blackwater fever, and has symptoms including chyluria and other and unspecified genitourinary symptoms. An important gene associated with Hemoglobinuria is PIGA (Phosphatidylinositol Glycan Anchor Biosynthesis Class A), and among its related pathways/superpathways are Innate Immune System and Cell surface interactions at the vascular wall. The drugs Miconazole and Clotrimazole have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, bone and kidney, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 73 Hemoglobinuria is a condition in which the oxygen transport protein hemoglobin is found in abnormally... more...

Related Diseases for Hemoglobinuria

Diseases related to Hemoglobinuria via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 423)
# Related Disease Score Top Affiliating Genes
1 paroxysmal nocturnal hemoglobinuria 1 33.1 PIGT PIGA
2 blackwater fever 31.5 MB HP G6PD
3 aplastic anemia 31.1 THBD SERPINC1 PIGA HLA-A CSF3 CD59
4 budd-chiari syndrome 31.0 SERPINC1 F2 CD59
5 myelodysplastic syndrome 31.0 PIGA HLA-A CSF3 CR1 CD59 CD55
6 acute kidney failure 30.8 MB HP F2
7 thrombosis 30.8 THBD SERPINC1 F2 CD55
8 thrombophilia 30.7 THBD SERPINC1 F2
9 anemia, autoimmune hemolytic 30.5 HP G6PD CD59 CD55 C3
10 multiple congenital anomalies-hypotonia-seizures syndrome 2 30.4 PIGT PIGA CD59
11 thrombotic microangiopathy 30.4 THBD HP
12 paroxysmal nocturnal hemoglobinuria 30.3 THBD SERPINC1 PLAUR PIGT PIGH PIGA
13 purpura 30.3 THBD SERPINC1 F2 C3
14 hypersplenism 30.3 SERPINC1 F2 CSF3
15 severe pre-eclampsia 30.2 SERPINC1 C5 C3
16 esophageal varix 30.1 SERPINC1 HP F2
17 thrombocytopenia 30.1 THBD SERPINC1 HP HLA-A F2 CSF3
18 thrombophilia due to thrombin defect 30.1 THBD SERPINC1 F2
19 varicose veins 30.1 THBD SERPINC1 F2
20 hemolytic anemia 30.0 THBD PIGT PIGA HP G6PD F2
21 branch retinal artery occlusion 30.0 SERPINC1 F2
22 retinitis pigmentosa and erythrocytic microcytosis 30.0 PIGA CSF3
23 autoimmune disease 30.0 HLA-A FCGR3B CD58 CD55 C3
24 genetic atypical hemolytic-uremic syndrome 30.0 THBD C3
25 leukemia, chronic lymphocytic 29.9 FCGR3B CSF3 CR1 CD59 CD58 CD55
26 splenic infarction 29.9 SERPINC1 F2
27 deficiency anemia 29.9 SERPINC1 MB HP G6PD F2 CSF3
28 sagittal sinus thrombosis 29.9 THBD SERPINC1 F2
29 hemolytic-uremic syndrome 29.9 THBD HP F2 CD55 C5 C3
30 anuria 29.9 MB HP F2
31 splenic sequestration 29.8 HP F2
32 essential thrombocythemia 29.8 THBD SERPINC1 F2 CSF3
33 thrombotic thrombocytopenic purpura 29.8 THBD SERPINC1 HP C3
34 central retinal artery occlusion 29.8 SERPINC1 F2
35 disseminated intravascular coagulation 29.8 THBD SERPINC1 MB F2
36 intracranial embolism 29.8 SERPINC1 F2
37 hepatic coma 29.7 SERPINC1 F2
38 pulmonary embolism 29.7 THBD SERPINC1 MB F2
39 thrombocytosis 29.7 SERPINC1 F2 CSF3
40 antiphospholipid syndrome 29.7 THBD SERPINC1 F2 C3
41 hemoglobinopathy 29.6 MB HP G6PD
42 bilirubin metabolic disorder 29.6 SERPINC1 HP G6PD F2 CSF3
43 homocysteinemia 29.6 THBD SERPINC1 F2
44 nephrotic syndrome 29.5 SERPINC1 PLAUR HP F2 C3
45 hemolytic uremic syndrome, atypical 1 29.5 THBD PIGA HP CR1 CD59 CD55
46 peripheral vascular disease 29.5 THBD SERPINC1 F2
47 central retinal vein occlusion 29.5 SERPINC1 G6PD F2
48 stroke, ischemic 29.1 THBD SERPINC1 MB F2
49 systemic lupus erythematosus 29.0 THBD HLA-A FCGR3B F2 CSF3 CR1
50 myocardial infarction 28.7 THBD SERPINC1 MB HP F2 CSF3

Graphical network of the top 20 diseases related to Hemoglobinuria:



Diseases related to Hemoglobinuria

Symptoms & Phenotypes for Hemoglobinuria

UMLS symptoms related to Hemoglobinuria:


chyluria; other and unspecified genitourinary symptoms

GenomeRNAi Phenotypes related to Hemoglobinuria according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.55 PLAUR
2 Decreased viability GR00221-A-1 9.55 PLAUR
3 Decreased viability GR00221-A-2 9.55 PLAUR
4 Decreased viability GR00221-A-4 9.55 PLAUR
5 Decreased viability GR00240-S-1 9.55 CD59
6 Decreased viability GR00249-S 9.55 C5 G6PD HLA-A HP PIGA
7 Decreased viability GR00386-A-1 9.55 C3 C5 CSF3 G6PD HLA-A MB
8 Decreased viability GR00402-S-2 9.55 G6PD

MGI Mouse Phenotypes related to Hemoglobinuria:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.13 C3 CD55 CD59 CSF3 FCGR3B G6PD
2 homeostasis/metabolism MP:0005376 10.1 C3 C5 CD55 CD59 F2 FCGR3B
3 immune system MP:0005387 9.93 C3 C5 CD55 CSF3 F2 FCGR3B
4 mortality/aging MP:0010768 9.8 C3 C5 CD55 CD59 F2 G6PD
5 renal/urinary system MP:0005367 9.28 C3 C5 CD55 CD59 CSF3 HP

Drugs & Therapeutics for Hemoglobinuria

Drugs for Hemoglobinuria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 75)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
2
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
3
Ravulizumab Approved, Investigational Phase 4 1803171-55-2
4
tannic acid Approved Phase 4 1401-55-4
5
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
6
Warfarin Approved Phase 4 81-81-2 6691 54678486
7
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030
8 Complement System Proteins Phase 4
9 Immunosuppressive Agents Phase 4
10 Immunologic Factors Phase 4
11 Antifungal Agents Phase 4
12 Anti-Infective Agents Phase 4
13 Anti-Bacterial Agents Phase 4
14 Antibiotics, Antitubercular Phase 4
15 Anticoagulants Phase 4
16
rituximab Approved Phase 3 174722-31-7 10201696
17
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
18
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
19
Iodine Approved, Investigational Phase 3 7553-56-2 807
20
Temazepam Approved, Investigational Phase 3 846-50-4 5391
21
Protein C Approved Phase 3
22 Cyclosporins Phase 3
23 Antibodies, Monoclonal Phase 3
24 Antilymphocyte Serum Phase 3
25 Muromonab-CD3 Phase 3
26 Immunoglobulins Phase 3
27 Antibodies Phase 3
28 Pharmaceutical Solutions Phase 3
29
Levamisole Approved, Investigational, Vet_approved, Withdrawn Phase 2 14769-73-4 26879
30
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
31
Melphalan Approved Phase 2 148-82-3 4053 460612
32
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
33
Lenograstim Approved, Investigational Phase 2 135968-09-1
34
Basiliximab Approved, Investigational Phase 2 179045-86-4, 152923-56-3
35
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
36
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
37
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
38
Mycophenolic acid Approved Phase 2 24280-93-1 446541
39
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492 6473866
40
Mesna Approved, Investigational Phase 2 3375-50-6 598
41
Phenylalanine Approved, Investigational, Nutraceutical Phase 2 63-91-2 6140
42
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
43 Hormones Phase 2
44 Antiparasitic Agents Phase 2
45 glucocorticoids Phase 2
46 Anthelmintics Phase 2
47 Hormone Antagonists Phase 2
48 Dermatologic Agents Phase 2
49 Folic Acid Antagonists Phase 2
50 Vitamin B9 Phase 2

Interventional clinical trials:

(show top 50) (show all 101)
# Name Status NCT ID Phase Drugs
1 An Open-Label Multi-Center Study of Eculizumab in Children and Adolescents With a Diagnosis of Paroxysmal Nocturnal Hemoglobinuria Completed NCT00867932 Phase 4 Eculizumab
2 Phase 4, Single-Arm Study of Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab Not yet recruiting NCT04320602 Phase 4
3 Sirolimus Combined With Low-dose Warfarin for the Treatment of Refractory Classic Paroxysmal Nocturnal Hemoglobinuria ,a Prospective Study Not yet recruiting NCT03866681 Phase 4 sirolimus
4 Investigational Product ; Coversin. Phase III Safety and Efficacy in Three-Part, Two-Arm, Randomised Open Label Evaluation in Patients With Paroxysmal Nocturnal Haemoglobinuria (PNH) Completed NCT03588026 Phase 3 rVA576
5 A Multicenter, Open Label, Randomized, Parallel-group Study of Efficacy and Safety of Eculizumab (JSC GENERIUM, Russia) vs. Soliris® (Alexion Pharma GmbH, Switzerland) in Patients With Paroxysmal Nocturnal Hemoglobinuria Completed NCT04463056 Phase 3
6 A Phase III, Randomized, Multi-Center, Open-Label, Active-Comparator Controlled Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Completed NCT03500549 Phase 3 APL-2;Soliris
7 TRIUMPH: A Hemoglobin Stabilization and Transfusion Reduction Efficacy and Safety Clinical Investigation, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Using Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients Completed NCT00112983 Phase 3
8 A Safety and Immunogenicity Study in Long-term Treatment of Eculizumab (JSC "GENERIUM", Russian Federation) in Patients With Paroxysmal Nocturne Hemoglobinuria, Who Have Been Involved Earlier in the Clinical Trials of Eculizumab Completed NCT04679103 Phase 3
9 Haploidentical Stem Cell Transplantation Utilizing Purified CD34+ Hematopoietic Cells for Patients With Hematologic Malignancies Completed NCT00186823 Phase 3 TBI, systemic chemotherapy and antibodies as follows:
10 Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH Completed NCT00122317 Phase 3 eculizumab
11 Safety in Hemolytic PNH Patients Treated With Eculizumab: a Multi-Center Open-Label Research Design Study Completed NCT00122304 Phase 3 eculizumab
12 Randomized, Open-Label, International, Multi-center, Comparative Study of Efficacy and Safety of BCD-148 (JSC BIOCAD, Russia) and Soliris® in Patients With Paroxysmal Nocturnal Hemoglobinuria Completed NCT04060264 Phase 3
13 Hematopoietic Stem Cell Transplantation Using Matched Unrelated Donor Peripheral Blood or Bone Marrow for Patients With Hematologic Malignancies Completed NCT00152139 Phase 3 Chemotherapy and antibodies
14 SHEPHERD: Safety in Hemolytic PNH Patients Treated With Eculizumab: A Multi-Center Open-Label Research Design Completed NCT00130000 Phase 3 Eculizumab
15 Randomized, Double-Blind, and Placebo-Controlled Study Using Eculizumab in Transfusion Dependent PNH Patients Completed NCT00122330 Phase 3 eculizumab
16 A Hemoglobin Stabilization and Transfusion Reduction Efficacy and Safety Clinical Investigation, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Using Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients Completed NCT00098280 Phase 3 Eculizumab
17 Randomized Comparison of Cyclophosphamide Versus Cyclophosphamide Plus Fludarabine In Addition To Anti-Thymocyte Globulin for the Conditioning Therapy in Allogeneic Hematopoietic Cell Transplantation for Bone Marrow Failure Syndrome Completed NCT00774527 Phase 3 Cyclophosphamide-fludarabine-anti thymocyte globulin
18 A Phase 3, Open-Label Study of ALXN1210 in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria (PNH) Recruiting NCT03406507 Phase 3
19 A Phase 3 Study of Danicopan (ALXN2040) as Add-on Therapy to a C5 Inhibitor (Eculizumab or Ravulizumab) in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Have Clinically Evident Extravascular Hemolysis (EVH) Recruiting NCT04469465 Phase 3 Danicopan;Placebo;C5 Inhibitor
20 A Phase III, Randomized, Open-Label, Active-Controlled, Multicenter Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors. Recruiting NCT04434092 Phase 3 Crovalimab;Eculizumab
21 A Phase III, Randomized, Open-Label, Active-Controlled, Multicenter Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors. Recruiting NCT04432584 Phase 3 Crovalimab;Eculizumab
22 CONSERVE: rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study Recruiting NCT03829449 Phase 3 rVA576 (Coversin)
23 A Randomized, Multicenter, Active-comparator Controlled, Open-label Trial to Evaluate Efficacy and Safety of Oral, Twice Daily LNP023 in Adult Patients With PNH and Residual Anemia, Despite Treatment With an Intravenous Anti-C5 Antibody. Recruiting NCT04558918 Phase 3 LNP023;Eculizumab;Ravulizumab
24 A Phase III, Multicenter, Single Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibition Recruiting NCT04654468 Phase 3 Crovalimab
25 A Randomized, Double-Blind, Active-Controlled Phase 3 Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH) Active, not recruiting NCT03818607 Phase 3 ABP 959;Eculizumab
26 A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Complement Inhibitor-Naïve Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Active, not recruiting NCT02946463 Phase 3
27 A Phase 3, Randomized, Multicenter, Open-Label, Controlled Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Active, not recruiting NCT04085601 Phase 3 APL-2
28 A Phase III Randomised, Double-blind, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB12 (Proposed Eculizumab Biosimilar) and Soliris® in Subjects With Paroxysmal Nocturnal Haemoglobinuria Active, not recruiting NCT04058158 Phase 3 SB12 (proposed eculizumab biosimilar);Soliris (eculizumab)
29 A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab Active, not recruiting NCT03056040 Phase 3
30 An Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria Enrolling by invitation NCT04162470 Phase 3 REGN3918
31 An Open Label, Non-Randomized, Multi-Center Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) Enrolling by invitation NCT03531255 Phase 3 Pegcetacoplan
32 A Multicenter, Single-arm, Open-label Trial to Evaluate Efficacy and Safety of Oral, Twice Daily Iptacopan in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy Not yet recruiting NCT04820530 Phase 3 Iptacopan (LNP023)
33 An Open Label, Multicenter Roll-over Extension Program (REP) to Characterize the Long-term Safety and Tolerability of Iptacopan (LNP023) in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Completed PNH Phase 2 and Phase3 Studies With Iptacopan Not yet recruiting NCT04747613 Phase 3 Iptacopan
34 Phase II Study of the Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria Unknown status NCT01642979 Phase 2 Levamisole+cyclosporin A+Glucocorticoids;cyclosporin A+Glucocorticoids;Glucocorticoids
35 Phase II Study of the Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013) Unknown status NCT01760096 Phase 2 Levamisole+cyclosporin A+Glucocorticoids;cyclosporin A+Glucocorticoids;Glucocorticoids
36 A Phase II Study of Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors for Treatment of Hematologic Malignancies and Hematopoietic Failure States Completed NCT00618969 Phase 2
37 Phase IIa, Open Label, Multiple Dose Study to Assess the Safety, Efficacy and Pharmacokinetics of Subcutaneously Administered APL-2 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH). Completed NCT03593200 Phase 2 Pegcetacoplan
38 A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation Completed NCT01529827 Phase 2 fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
39 A Reduced Intensity Conditioning Regimen With CD3-Depleted Hematopoietic Stem Cells to Improve Survival for Patients With Hematologic Malignancies Undergoing Haploidentical Stem Cell Transplantation Completed NCT00566696 Phase 2 Fludarabine;Thioplex®;L-phenylalanine mustard;Mycophenolate mofetil;Rituxan™;Alemtuzumab;Cyclophosphamide;Anti-thymocyte globulin (Rabbit);G-CSF;Muromonab
40 A Phase II Study of Reduced-Intensity Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT) for Treatment of Hematologic Malignancies and Hematopoietic Failure States Completed NCT00997386 Phase 2 busulfan, and melphalan, and alemtuzumab
41 Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms Completed NCT02591862 Phase 2 Coversin
42 HLA-HAPLOIDENTICAL FAMILIAL DONOR HEMATOPOIETIC CELL TRANSPLANTATION AFTER REDUCED INTENSITY CONDITIONING OF BUSULFAN, FLUDARABINE, AND ANTI-THYMOCYTE GLOBULIN FOR PATIENTS WITH BONE MARROW FAILURE SYNDROME - A PHASE 2 STUDY Completed NCT00731328 Phase 2
43 Phase II Trial of Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Treatment of Adult Patients (>18 Years) With Lymphohematopoietic Disorders Completed NCT00587054 Phase 2 cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant
44 Phase II Clinical Study of Eculizumab (h5G1.1-mAb) in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients: Extension Study to C07-001 Protocol Completed NCT01194804 Phase 2 Eculizumab
45 Phase II Clinical Study of Eculizumab (h5G1.1-mAb) in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Completed NCT01192399 Phase 2
46 Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent GVHD After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer Completed NCT00975975 Phase 2 Basiliximab
47 A Phase 1/2 Single-ascending and Multiple-ascending Dose, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered ALN-CC5 in Healthy Adult Volunteers and Patients With Paroxysmal Nocturnal Hemoglobinuria Completed NCT02352493 Phase 1, Phase 2 ALN-CC5;Sterile Normal Saline (0.9% NaCl)
48 Low-Dose TBI Dose Escalation to Decrease Risks of Progression and Graft Rejection After Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning as Treatment for Untreated Myelodysplastic Syndrome or Myeloproliferative Disorders - A Multi-Center Trial Completed NCT00397813 Phase 2 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil
49 Haploidentical Hematopoietic Stem Cell Transplantation Utilizing Partial T-Cell Depletion as Immunotherapy for Hematologic Malignancies Completed NCT00143559 Phase 2 Systematic chemotherapy and antibodies
50 High Dose Cyclophosphamide for the Treatment of Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria Completed NCT00004464 Phase 2 cyclophosphamide;filgrastim

Search NIH Clinical Center for Hemoglobinuria

Cochrane evidence based reviews: hemoglobinuria

Genetic Tests for Hemoglobinuria

Genetic tests related to Hemoglobinuria:

# Genetic test Affiliating Genes
1 Hemoglobinuria 29

Anatomical Context for Hemoglobinuria

MalaCards organs/tissues related to Hemoglobinuria:

40
Bone Marrow, Bone, Kidney, Myeloid, Monocytes, Neutrophil, Endothelial

Publications for Hemoglobinuria

Articles related to Hemoglobinuria:

(show top 50) (show all 3523)
# Title Authors PMID Year
1
The prevalence of G6PD deficiency in blood transfusion recipients. 61 54
17364999 2007
2
[Post-hemolytic renal failure in children with glucose-6-phosphate dehydrogenase deficiency at the University Hospital Center in Lome]. 61 54
12910652 2003
3
Ethanol sclerotherapy of venous malformations: evaluation of systemic ethanol contamination. 61 54
11340138 2001
4
Acute myelogenous leukemia with PIG-A gene mutation evolved from aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome. 61 54
11372733 2001
5
Paroxysmal nocturnal hemoglobinuria: An acquired genetic disease. 54 61
10539884 1999
6
Paroxysmal nocturnal hemoglobinuria: molecular pathogenesis and molecular therapeutic approaches. 61 54
9844822 1998
7
Blackwater fever in southern Vietnam: a prospective descriptive study of 50 cases. 54 61
8953071 1996
8
Serum transcobalamin II level in glucose-6-phosphate dehydrogenase deficient subjects with typhoid fever. 54 61
8708525 1996
9
Persistently elevated serum transcobalamin II in a patient with cerebral malaria and typhus infections. 54 61
7622977 1995
10
Repeated large-dose haptoglobin therapy in an extensively burned patient: case report. 54 61
8163802 1994
11
Hemolytic effect of the Amplatz thrombectomy device. 61 54
8136596 1994
12
[Intensive care of a postpartum patient complicated with HELLP syndrome]. 54 61
8320814 1993
13
Regulation of renal function in thermal injury. 54 61
2147724 1990
14
[Administration of haptoglobin in ABO incompatible bone marrow transplantation]. 61 54
2255063 1990
15
Utility of FLAER and CD157 in a five-color single-tube high sensitivity assay, for diagnosis of Paroxysmal Nocturnal Hemoglobinuria (PNH)-A standalone flow cytometry laboratory experience. 61
33058446 2021
16
Treatment of paroxysmal nocturnal hemoglobinuria in pregnancy with eculizumab: A case report. 61
33665137 2021
17
Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics. 61
33687995 2021
18
Hemoglobinuria for the early identification of STEC-HUS in high-risk children: data from the ItalKid-HUS Network. 61
33759020 2021
19
Erythrophagocytosis in a young adult with mycoplasma pneumonia-induced paroxysmal cold hemoglobinuria. 61
33704394 2021
20
Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria. 61
33341510 2021
21
How I treat paroxysmal nocturnal hemoglobinuria. 61
33512400 2021
22
Long Non-coding RNA MALAT1 Contributed to the Proliferation of PNH Clone in Paroxysmal Nocturnal Hemoglobinuria Patients. 61
33726486 2021
23
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. 61
33730455 2021
24
Hemolytic crisis in a patient treated with eculizumab for paroxysmal nocturnal hemoglobinuria possibly triggered by SARS-CoV-2 (COVID-19): a case report. 61
33170342 2021
25
Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria. 61
33047216 2021
26
One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab. 61
33301613 2021
27
Mutational landscape and its clinical significance in paroxysmal nocturnal hemoglobinuria. 61
33727526 2021
28
A Nationwide Analysis of Budd-Chiari Syndrome in the United States. 61
33746442 2021
29
JAK2V617F positive polycythemia vera with paroxysmal nocturnal hemoglobinuria and visceral thromboses: a case report and review of the literature. 61
33691713 2021
30
Paroxysmal Nocturnal Hemoglobinuria Presenting with Hemorrhagic Esophageal Varices. 61
33121958 2021
31
Paroxysmal Nocturnal Hemoglobinuria: Case Report of a Rare Cause of Thrombosis in the Pediatric Age. 61
31842179 2021
32
Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia. 61
33664463 2021
33
Very severe aplastic anemia in an 80-year-old man. 61
33768838 2021
34
Relationship between immune status after ATG treatment and PNH clone evolution in patients with severe aplastic anemia. 61
33249661 2021
35
Difficult Cases of Paroxysmal Nocturnal Hemoglobinuria: Diagnosis and Therapeutic Novelties. 61
33804461 2021
36
Dental infection associated with exuberant gingival necrosis in a patient with paroxysmal nocturnal hemoglobinuria: A case report. 61
33368558 2021
37
Risk of Disseminated Gonococcal Infections With Terminal Complement Blockade. 61
33560079 2021
38
Clinical study of transjugular intrahepatic portosystemic shunt combined with AngioJet thrombectomy for acute portal vein thrombosis in non-cirrhosis. 61
33578540 2021
39
Targeting the complement system in neuromyelitis optica spectrum disorder. 61
33513036 2021
40
[Thrombocytopenia and thromboses in a young woman]. 61
33005993 2021
41
Safety of current treatments for paroxysmal nocturnal hemoglobinuria. 61
33249943 2021
42
Bone Marrow of Contention: A Rare Case of Recurrent Acute Hepatitis. 61
33089481 2021
43
Clinical Profile and Outcome of Childhood Autoimmune Hemolytic Anemia: A Single Center Study. 61
33634793 2021
44
Nanobodies Provide Insight into the Molecular Mechanisms of the Complement Cascade and Offer New Therapeutic Strategies. 61
33671302 2021
45
Cerebrovascular manifestations in hematological diseases: an update. 61
33586004 2021
46
Acute Distress Respiratory Syndrome and Cardiac Shock after AngioJet Thrombectomy for Acute Occlusion of an Aortic Endograft. 61
32927032 2021
47
Silicone Oil Decreases Biofilm Formation in a Capacitance-Based Automatic Urine Measurement System. 61
33435177 2021
48
Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria. 61
31949012 2021
49
Paroxysmal nocturnal hemoglobinuria complicated with essential thrombocythemia harboring concomitant PIGA, CALR, and ASXL1 mutations. 61
33491136 2021
50
Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with paroxysmal nocturnal hemoglobinuria. 61
32889696 2021

Variations for Hemoglobinuria

Expression for Hemoglobinuria

Search GEO for disease gene expression data for Hemoglobinuria.

Pathways for Hemoglobinuria

Pathways related to Hemoglobinuria according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.78 PLAUR HP HLA-A FCGR3B CSF3 CR1
2
Show member pathways
11.98 THBD F2 CEACAM8 CD58
3
Show member pathways
11.85 CR1 CD59 CD55 C5 C3
4 11.75 CSF3 CEACAM8 CD59
5
Show member pathways
11.72 CR1 CD59 CD55 C5 C3
6 11.65 FCGR3B C5 C3
7 11.62 CSF3 CR1 CD59 CD55
8 11.58 FCGR3B CR1 C3
9
Show member pathways
11.54 CD55 C5 C3
10 11.44 THBD SERPINC1 PLAUR F2 CR1 CD59
11
Show member pathways
11.35 PLAUR PIGT PIGH PIGA FCGR3B
12
Show member pathways
11.16 PIGT PIGH PIGA

GO Terms for Hemoglobinuria

Cellular components related to Hemoglobinuria according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.07 SERPINC1 PLAUR HP FCGR3B F2 CSF3
2 extracellular space GO:0005615 10.06 THBD SERPINC1 HP F2 CSF3 CEACAM8
3 endoplasmic reticulum membrane GO:0005789 9.99 PLAUR PIGT PIGH PIGA HLA-A CD59
4 endoplasmic reticulum lumen GO:0005788 9.8 SERPINC1 PLAUR F2 C3
5 specific granule membrane GO:0035579 9.65 PLAUR CEACAM8 CD59
6 blood microparticle GO:0072562 9.62 SERPINC1 HP F2 C3
7 ficolin-1-rich granule membrane GO:0101003 9.61 CR1 CD58 CD55
8 cell surface GO:0009986 9.61 THBD PLAUR HLA-A CR1 CEACAM8 CD59
9 secretory granule membrane GO:0030667 9.56 FCGR3B CR1 CD58 CD55
10 anchored component of membrane GO:0031225 9.55 PLAUR FCGR3B CEACAM8 CD59 CD55
11 extracellular exosome GO:0070062 9.47 SERPINC1 MB HP HLA-A G6PD FCGR3B
12 glycosylphosphatidylinositol-N-acetylglucosaminyltransferase (GPI-GnT) complex GO:0000506 9.46 PIGH PIGA

Biological processes related to Hemoglobinuria according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 10.01 HP HLA-A CR1 CD55 C5 C3
2 innate immune response GO:0045087 9.98 HLA-A CR1 CD55 C5 C3
3 immune response GO:0006955 9.96 HLA-A FCGR3B CSF3 CEACAM8 C3
4 cell surface receptor signaling pathway GO:0007166 9.89 FCGR3B F2 CD59 C5
5 leukocyte migration GO:0050900 9.81 THBD F2 CEACAM8 CD58
6 complement activation, classical pathway GO:0006958 9.73 CR1 CD55 C5 C3
7 hemostasis GO:0007599 9.65 THBD SERPINC1 F2
8 blood coagulation GO:0007596 9.65 THBD SERPINC1 PLAUR F2 CD59
9 preassembly of GPI anchor in ER membrane GO:0016254 9.58 PIGH PIGA
10 regulation of blood coagulation GO:0030193 9.57 SERPINC1 F2
11 negative regulation of fibrinolysis GO:0051918 9.55 THBD F2
12 GPI anchor biosynthetic process GO:0006506 9.54 PIGT PIGH PIGA
13 negative regulation of platelet activation GO:0010544 9.52 THBD F2
14 regulation of complement-dependent cytotoxicity GO:1903659 9.49 CD59 CD55
15 negative regulation of complement activation GO:0045916 9.46 CR1 CD55
16 regulation of complement activation GO:0030449 9.43 F2 CR1 CD59 CD55 C5 C3
17 negative regulation of activation of membrane attack complex GO:0001971 9.4 CR1 CD59
18 complement activation, alternative pathway GO:0006957 9.33 CR1 C5 C3
19 positive regulation of activation of membrane attack complex GO:0001970 9.32 CR1 C3
20 neutrophil degranulation GO:0043312 9.28 PLAUR HP FCGR3B CR1 CEACAM8 CD59

Molecular functions related to Hemoglobinuria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.1 PLAUR HLA-A F2 CD58 C5 C3
2 phosphatidylinositol N-acetylglucosaminyltransferase activity GO:0017176 8.96 PIGH PIGA

Sources for Hemoglobinuria

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....